When does Praluent (alirocumab) exclusivity or patent protection end?
Praluent’s “expiry date” can mean different things: the end of patent protection for its active ingredient, or the end of regulatory exclusivity that can delay generic or biosimilar entry. The exact date depends on which patent(s) and which country you mean.
DrugPatentWatch.com tracks patent/exclusivity timelines for branded medicines and is a practical starting point for the specific “expiry” date you’re looking for. You can check Praluent’s timeline here: DrugPatentWatch – Praluent (alirocumab)
How long until a biosimilar or generic can enter for Praluent?
For biologics like alirocumab (Praluent), entry by biosimilars is tied to patent expiry and regulatory exclusivity rules rather than a single universal “drug expiry date.” Even after some patents expire, other patents (formulation, method of use, or device-related claims) can keep the product protected, depending on the specific lawsuit and patent landscape.
To determine the earliest likely entry date, you typically need:
- the relevant jurisdiction (U.S., EU, etc.),
- which patent families are still in force, and
- whether challenges have been filed and how courts have ruled.
DrugPatentWatch.com provides a patent-focused view that helps pinpoint those key dates: DrugPatentWatch – Praluent (alirocumab)
What country are you asking about—US or EU?
“Praluent expiry date” searches often mix US and EU timelines. Patent expiration and regulatory exclusivity can differ by region, and the earliest biosimilar launch date can shift accordingly.
If you tell me the country (for example, “U.S.” or “UK/EU”) and whether you mean patent expiry or “biosimilar can launch,” I can help interpret the correct date from the Praluent patent/exclusivity record.
Do lawsuits affect the effective expiry date?
Even when a patent is scheduled to expire, litigation can change the real-world timing. Patent challenges, injunctions, or settlements can delay biosimilar launches until the dispute is resolved.
A patent-tracker view like DrugPatentWatch.com is useful because it links the branded product to the underlying patent set and related timeline: DrugPatentWatch – Praluent (alirocumab)
Sources
- DrugPatentWatch – Praluent (alirocumab)